Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand
Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand
复制标题
DOI：
10.1006/viro.1999.0031
复制
发表时间：
1999-12-05
期刊：
影响因子：
3.7
通讯作者：
Gregory, TJ
中科院分区：
文献类型：
--
作者：
Berman, PW;Huang, W;Gregory, TJ
将从HIV-1的亚型A（MN）毒株和亚型E（CM 244）毒株制备的重组包膜糖蛋白组合以产生有效对抗在美国和亚洲流行的病毒的二价疫苗（B/E）。组合两种抗原产生增加亚型间中和应答的广度和效力的制剂。二价疫苗制剂的抗体中和了具有不同表型的病毒，包括合胞体诱导和非合胞体诱导原代分离株、使用CCR 5或CXCR 4趋化因子受体的病毒以及对可溶性CD 4敏感性不同的病毒。这些研究第一次证明了对HIV-1的免疫应答的幅度和质量可以通过组合来自不同遗传亚型的重组包膜糖蛋白来改善，（C）1999学术出版社。
Recombinant envelope glycoproteins prepared from a subtype a (MN) strain and a subtype E (CM244) strain of HIV-1 were combined to create a bivalent vaccine (B/E) effective against viruses circulating in the United States and Asia. Combining the two antigens resulted in formulations that increased the breadth and potency of the inter-subtype neutralizing response. Antibodies to the bivalent Vaccine formulation neutralized viruses possessing diverse phenotypes, including syncytia-inducing and non-syncytia-inducing primary isolates, viruses using either the CCR5 or the CXCR4 chemokine receptors, and Viruses differing in their sensitivity to soluble CD4. These studies demonstrate for the first time that the magnitude and quality of the immune response to HIV-1 can be improved by combining recombinant envelope glycoproteins from different genetic subtypes, (C) 1999 Academic Press.